| Huidige behandelopties |
Glucagon injectie, of glucose injectie |
| Therapeutische waarde |
Geen oordeel
Deze inschatting doet geen uitspraak over de mogelijke opname in het pakket.
|
| Onderbouwing |
Deze nieuwe formulering is wezenlijk anders, makkelijker toe te dienen, alternatief voor injectie. |
| Behandelduur |
levenslang |
| Dosis per toediening |
3 mg |
| Bronnen |
NCT02402933; clinical trials. gov.; Stenninger Diabetialogia 1993
Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting
Elizabeth R. Seaquist, et al. Diabetes Obes Metab.2018;20:13161320.https://doi.org/10.1111/dom.13278 .
A phase 3 multicenter, open‐label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting Larry C Deeb, et al. Pediatric Diabetes.2018;19:1007–1013
Sherr JL et al. Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes. Diabetes Care. 2016 Apr;39(4):555-62.
Rickels MR et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care. 2016 Feb;39(2):264-70.
Simulated Usability Study: Yale JF et al. Faster Use and Fewer Failures with Needle-Free Nasal Glucagon Versus Injectable Glucagon in Severe Hypoglycemia Rescue: A Simulation Study. Diabetes Technol Ther. 2017 Jul;19(7):423-432. |